Eyenovia

Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

News

Movers

EYEN

Eyenovia, Inc. (NASDAQ: EYEN) shares are trading higher Wednesday after the company announced it had regained compliance with Nasdaq listing requirements. 

Eyenovia Shares Surge After Regaining Nasdaq Compliance: What&#39;s Going On?

benzinga_deal_dispatch2

FUBO

PAYX

PYCR

TSX:CSO

TSX:TD

TSXV:CSO

VSTO

TD Bank is considering a Charles Schwab stake sale while Disney inks deal with FuboTV. Meanwhile, bankruptcy cases spiked in 2024.

Deal Dispatch: TD Bank To Sell Charles Schwab Stake? Eyenovia, Smart Share Hit Auction Block

movers image

Pre-Market Outlook

Markets

Trading Ideas

AMBO

ASNS

BHAT

BLBX

BNAI

CETX

DSGN

INSE

MULN

OPTT

SGMO

WATT

Why Cemtrex Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket

Eyenovia Inc

Health Care

Press Releases

Eyenovia Provides Update on Phase 3 CHAPERONE Study

Eyenovia Provides Update on Restructuring Efforts

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

Financing

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

General

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote "FOR" Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Eyenovia Announces 1-for-80 Reverse Stock Split

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Akanda

Artelo Biosciences

Avenue Therapeutics

Biofrontera

CNS Pharma

China Pharma Holding

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

China SXT Pharmaceuticals, Inc. - Common Stock

China SXT Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

TNF Pharmaceuticals

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

cbdMD

HC Wainwright & Co.

Comments

Eyenovia

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga